» Articles » PMID: 28288641

SOX2 Regulates Multiple Malignant Processes of Breast Cancer Development Through the SOX2/miR-181a-5p, MiR-30e-5p/TUSC3 Axis

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2017 Mar 15
PMID 28288641
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High levels of SOX2 protein are correlated with increased dissemination of breast cancer. However, the underlying molecular mechanisms are not fully understood.

Methods: In this study we investigate the role of SOX2 in breast cancer metastasis using multiple in vitro and in vivo assays including cell culture, shRNA-mediated knockdown, wound healing, colony formation, transwell chamber, xenograft and tail vein injection. Moreover, western blot, immunostaining, microarray and real-time PCR were used to determine the change of protein and miRNA levels. Luciferase assays were also used to evaluate activity which TUSC3 is a target of miR-181a-5p and miR-30e-5p, and the clinical survival relevance was analyzed by Kaplan-Meier analysis.

Results: We identified a novel pathway involving SOX2 regulation of microRNAs to control the proliferation and migration of breast cancer cells. shRNA-mediated knockdown of SOX2 inhibits breast cancer cell expansion and migration. More importantly, we found that these changes are accompanied by significant reduction in the levels of two microRNAs, miR-181a-5p and miR-30e-5p. Overexpression of these two microRNAs leads to reduced protein levels of Tumor Suppressor Candidate 3 (TUSC3) in breast cancer cells; mutations of the potential binding sites in the 3'-UTR of TUSC3 abrogate the inhibitory effects of the microRNAs. We further found that upregulation of TUSC3 expression leads to reduced proliferation and migration of breast cancer cells. In human breast cancer samples the levels of TUSC3 protein are inversely correlated with those of SOX2 protein.

Conclusions: Taken together, our work reveals a novel SOX2-mediated regulatory axis that plays critical roles in the proliferation, migration and invasiveness of breast cancer cells. Targeting this axis may provide beneficial effect in the treatment of breast cancer.

Citing Articles

Dexamethasone-tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells.

Gaballah A, Elsherbiny A, Sharaky M, Hamed N, Raslan N, Almilaibary A Biosci Rep. 2024; 44(7).

PMID: 38864530 PMC: 11230869. DOI: 10.1042/BSR20240367.


Hypoxia-induced miR-181a-5p up-regulation reduces epirubicin sensitivity in breast cancer cells through inhibiting EPDR1/TRPC1 to activate PI3K/AKT signaling pathway.

Zhang Y, Guan Y, Zheng X, Li C BMC Cancer. 2024; 24(1):167.

PMID: 38308220 PMC: 10835859. DOI: 10.1186/s12885-024-11906-6.


Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer.

Zu L, He J, Zhou N, Tang Q, Liang M, Xu S Cell Death Dis. 2023; 14(12):798.

PMID: 38057344 PMC: 10700602. DOI: 10.1038/s41419-023-06286-x.


Targeting the SOX2/CDP protein complex with a peptide suppresses the malignant progression of esophageal squamous cell carcinoma.

Chen Y, Zhang K, Zhang R, Wang Z, Yang L, Zhao T Cell Death Discov. 2023; 9(1):399.

PMID: 37891174 PMC: 10611744. DOI: 10.1038/s41420-023-01693-7.


miR-30e-5p-mediated FOXD1 promotes cell proliferation by blocking cellular senescence and apoptosis through p21/CDK2/Rb signaling in head and neck carcinoma.

Wu T, Yang Z, Chen W, Jiang M, Xiao Z, Su X Cell Death Discov. 2023; 9(1):295.

PMID: 37563111 PMC: 10415393. DOI: 10.1038/s41420-023-01571-2.


References
1.
Liu K, Jiang M, Lu Y, Chen H, Sun J, Wu S . Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell. 2013; 12(3):304-15. PMC: 3594795. DOI: 10.1016/j.stem.2013.01.007. View

2.
Mohorko E, Glockshuber R, Aebi M . Oligosaccharyltransferase: the central enzyme of N-linked protein glycosylation. J Inherit Metab Dis. 2011; 34(4):869-78. DOI: 10.1007/s10545-011-9337-1. View

3.
Conway K, Edmiston S, Tse C, Bryant C, Kuan P, Hair B . Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2015; 24(6):921-30. PMC: 4452445. DOI: 10.1158/1055-9965.EPI-14-1228. View

4.
Horak P, Tomasich E, Vanhara P, Kratochvilova K, Anees M, Marhold M . TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. Sci Rep. 2014; 4:3739. PMC: 3894551. DOI: 10.1038/srep03739. View

5.
Veitonmaki N, Hansson M, Zhan F, Sundberg A, Lofstedt T, Ljungars A . A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013; 23(4):502-15. DOI: 10.1016/j.ccr.2013.02.026. View